Current and emerging medical therapies in the treatment of glaucoma

Bibliography

• Falkenberg HK, Bex PJ. Sources of motion-sensitivity loss in glaucoma. Invest Ophthalmol Vis Sci 2007;16(6):2913-21
   Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 95-7
   Google Scholar
• Available from: http://one.aao.org/CE/PracticeGuidelines/PPP.aspx
   Google Scholar
• Coleman AL. Glaucoma. Lancet 1999;354(9192):1803-10
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363(9422):1711-20
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 93-113
   Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 12
   Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 22-4
   Google Scholar
• Quigley HA. Number of people with glaucoma wordwide. Br J Ophthalmol 1996;80:389-93
   PubMed Web of Science ®Google Scholar
• Martus P, Stroux A, Budde WM, Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma. Am J Ophthalmol 2005;139(6):999-1009
   PubMed Web of Science ®Google Scholar
• Leske MC, Wu SY, Hennis A, ; BESs Study Group. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology 2008;115(1):85-93
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, ; for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, ; for the Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 118
   Google Scholar
• Walland MJ, Carassa RG, Goldberg I, Failure of medical therapy despite normal intraocular pressure. Clin Exp Ophthalmol 2006;34(9):827-36
   PubMed Web of Science ®Google Scholar
• Strahlman E, Tipping R, Vogel R. A double-masked randomized 1-year study comparing dorzolamide, timolol and betalol. International Dorzolamide study group. Arch Ophthalmol 1995;113:1009-16
   PubMed Web of Science ®Google Scholar
• Baudouin C, Hamard P, Liang H. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004;111:2186-92
   PubMed Web of Science ®Google Scholar
• Pisella P-J, Debbasch C, Hamard P. Conjunctival pro-inflammatory and pro-apoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45(5):1360-8
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 134-5
   Google Scholar
• Adamsons IA, Polis A, Ostrov CS. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. J Glaucoma 1998;7(6):395-401
   PubMed Web of Science ®Google Scholar
• Rusk C, Sharpe E, Laurence J. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group. Clin Ther 1998;20(3):454-66
   PubMed Web of Science ®Google Scholar
• Stewart WC, Halper LK, Johnson-Pratt L. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol. J Ocul Pharmacol Ther 2002;18(3):211-20
   PubMed Web of Science ®Google Scholar
• LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998;105:1960-67
   PubMed Web of Science ®Google Scholar
• Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127(1):20-6
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11(2):119-26
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135(5):688-703
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin N. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2004;137(1):210-11
   PubMed Web of Science ®Google Scholar
• Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003;19(1):23-35
   PubMed Web of Science ®Google Scholar
• Honrubia F, Garcia-Sanchez J, Polo V, Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. Br J Ophthalmol 2009;93:316-21
   PubMed Web of Science ®Google Scholar
• Schwartz GF. Current use of latanoprost and travoprost: a six-month, population-based cohort study. Presented as poster session at annual meeting of American Glaucoma Society; Snowbird Utah; 2005
   Google Scholar
• Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004;137(1 Suppl):S13-16
   PubMedGoogle Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137(1 Suppl):S3-12
   PubMedGoogle Scholar
• Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003;19:23-35
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medications changes in glaucoma patients treated initially with prostaglandin analogs. J Ocul Pharmacol Ther 2009;25:555-62
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Hahn SR, Gelb L, The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009;24:49-56
   Google Scholar
• Arias A, Schargel K, Ussa F, Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol 2010;4:261-7
   PubMedGoogle Scholar
• Reardon G, Schwarts GF, Mozaffari E. patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137:S3-12
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 144-5
   Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009;116(11 Suppl):S30-6
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE, editors, Terminology and guidelines for glaucoma. 3rd edition. Savona, Dogma s.r.l.; 2008. p. 117-31
   Google Scholar
• Jaenen N, Baudouin C, Pouliquen P. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17(3):341-9
   PubMed Web of Science ®Google Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86(7):716-26
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Goldschild M, Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;105:556-56
   Web of Science ®Google Scholar
• Debbasch C, Brignole F, Pisella PJ. Preservatives contribution in oxidative stress and apoptosis on chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:642-52
   PubMed Web of Science ®Google Scholar
• Brasnu E, Brignole-Baudouin F, Riancho L. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res 2008;33:303-12
   PubMed Web of Science ®Google Scholar
• Debbasch C, Pisella PJ, De Saint Jean M. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:2525-33
   PubMed Web of Science ®Google Scholar
• Baudoin C, Labbe A, Liang H, Preservatives in eyedrops: the good, the bad and the ugly. Pro Ret Eye Res 2010;29:312-34
   PubMed Web of Science ®Google Scholar
• Baudoin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42
   PubMed Web of Science ®Google Scholar
• Denis P, Demailly P, Saraux H. Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension. J Fr Ophthalmol 1993;16:297-303
   PubMedGoogle Scholar
• Easty DL, Nemeth-Wasmer G, Vounatsos JP, Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol 2006;90:574-8
   PubMed Web of Science ®Google Scholar
• Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preserve-free tafluprost. Ophthalmic Res 2009;41:118-22
   PubMed Web of Science ®Google Scholar
• Lebrun-Julien F, Di Polo A. Molecular and cell-based approaches for neuroprotection in glaucoma. Optom Vis Sci 2008;85(6):417-24
   PubMed Web of Science ®Google Scholar
• Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007;67(5):725-59
   PubMed Web of Science ®Google Scholar
• Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009;87(4):450-4
   PubMed Web of Science ®Google Scholar
• Lambiase A, Aloeb L, Centofanti M, Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications. PNAS 2009;106(32):13469
   PubMed Web of Science ®Google Scholar
• Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to th treatment of glaucoma. J Neurosci Res 2002;15:143-8
   Google Scholar
• Lebrun-Julien F, Di Polo A. Molecular and cell-based approaches for neuroprotection in glaucoma. Opt Vis Sci 2008;85:417-24
   PubMed Web of Science ®Google Scholar
• Caprioli J, Ishii Y, Kwong JM. Retinal ganglion cell protection with geranylgeranylacetone, aheatshock protein inducer, in a rat glaucoma model. Trans Am Ophthalmol Soc 2003;101:39-50
   PubMedGoogle Scholar
• Nucci C, Tartaglione R, cerulli A, Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol 2007;82:397-406
   PubMed Web of Science ®Google Scholar
• Hirooka K, Tokuda M, Myamoto O, The Ginko biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res 2004;28:153-7
   PubMed Web of Science ®Google Scholar
• Falsini B, marangoni D, Salgarello T, Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram Graefes Arch Clin Exp Ophthalmol 2008;247(9):1223-33
   Google Scholar
• Baudouin C, Liang H. Vaccine for glaucoma, Myth or reality? J Fr Ophthalmol 2006;29:8-12
   Google Scholar
• Laengle UW, Markstein R, Pralet D, Effects of latanoprost, timolol and GLC756, a novel dopamine D82)agonist and D(1) antagonist on LTC(4) release after rat mast cell activation. Clin Exp Ophthalmol 2007;35(7):645-50
   PubMed Web of Science ®Google Scholar
• Company Web Page, Merz, 10 July 2000
   Google Scholar
• ClinicalTrials.gov, 12 May 2009 & 30 June 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00626782
   Google Scholar
• Press release, Can-Fite, 6 November 2007 & 18 August 2008
   Google Scholar
• Company Web Page, Inotek, 2 June & 12 December 2006; Press release, Inotek, 8 April 2008
   Google Scholar
• Press release, Inotek, 17 June 2010. Available from: http://www.inotekcorp.com/press_room/news_37.asp
   Google Scholar
• Press releases, Inotek, 18 June 2008 & 28 April & 25 June 2009
   Google Scholar
• Data Book, Santen, 13 May 2002
   Google Scholar
• Press release, Danube, 17 May 2007; ClinicalTrials.gov Web page, 2 June 2009, NCT00683501
   Google Scholar
• Company Web Page, Alcon, 26 May 2009; ClinicalTrials.gov Web Page, 10 August 2007, NCT00465621
   Google Scholar
• ClinicalTrials.gov, 15 Sep 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00620256
   Google Scholar
• ClinicalTrials.gov, 15 Sep 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00372931
   Google Scholar
• ClinicalTrials.gov, 14 September 2010
   Google Scholar
• Peral A, Loma P, Medeiro A, Effect of several si RNA in the treatment of ocular hypertension and glaucoma. Invest Ophthalmol Vis Sci 2007;48:E-Abstract 4808
   Google Scholar
• Press release, Sylentis, 22 July 2009
   Google Scholar
• Press release, Sylentis, 6 Sep 2010. Available from: http://www.sylentis.com/index.php?option=com_content&view=article&id=36%3Asylentis-recibe-autorizacion-para-comenzar-un-nuevo-ensayo-clinico-de-fase-iii-con-syl040012-en-pacientes-para-el-tratamiento-de-la-presion-intraocular-elevada-y-glaucoma-&catid=4%3Anoticias-sylentis&Itemid=35&lang=en; ClinicalTrials.gov, 26 October 2010, http://clinicaltrials.gov/ct2/show/NCT01227291
   Google Scholar
• Company Web Page, Aerie, 16 October 2008 & 17 July 2009
   Google Scholar
• Company Web Page, Aerie, 2 December 2008
   Google Scholar
• Company Web Page, Aerie, 13 July 2009; Press release, Aerie, 22 October 2009; ClinicalTrials.gov, 26 August 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00902200
   Google Scholar
• Company pipeline, Aerie, 23 October 2009; ClinicalTrials.gov, 26 August 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01060579
   Google Scholar
• ClinicalTrials.gov Web Page, 6 January 2009, NCT00809848. Available from: http://clinicaltrials.gov/ct2/show/NCT00809848
   Google Scholar
• Company Web Page, Chakshu, 30 January 2009
   Google Scholar
• ClinicalTrials.gov Web Page, 9 October 2009, NCT00825396
   Google Scholar
• Direct communications, Teva, February 1996 & 13 February 2000
   Google Scholar
• Company Web Page, Proneuron, 2 February & 23 March 2005
   Google Scholar
• Company Web Page, Novagali, 5 December 2005 & 24 November 2010, http://www.novagali.com/en/eye-therapy/pipeline/; Press release, Novagali, 5 May 2009
   Google Scholar
• Press releases, NicOx, 12 February & 28 March 2007; Company pipeline, NicOx, 12 Oct 2009
   Google Scholar
• Press release, NicOx, 12 February 2007; Press release, NiCox, 15 November 2010. Available from: http://www.nicox.com/upload/PR_BOL303259X_Ph2_151110_EN.pdf
   Google Scholar
• Invest presentation, SPARC, May 2010, Slide 34 & 35 of 63. Available from: http://www.sunpharma.in/Investor%20Presentation%20SPARC%20May%202010.pdf; ClinicalTrials.gov, 16 Aug 2010, http://clinicaltrials.gov/ct2/show/NCT00947661
   Google Scholar
• ClinicalTrials.gov Web Page, 27 February 2009, NCT00848536
   Google Scholar
• Vistakon Johnson & Johnson ClinicalTrials.gov Web Page, 11 February 2009, NCT00824720
   Google Scholar
• Company Web Page, Allergan, 20 May 2009
   Google Scholar
• ClinicalTrials.gov, 13 September 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00693485
   Google Scholar
• Company Web Page, Aerie, 16 October 2008 & 20 July 2009
   Google Scholar
• Company Web Page, Allergan, 20 May 2009; ClinicalTrials.gov Web Page, 4 May 2010, NCT01110499
   Google Scholar
• Company pipeline, Pfizer, 28 February 2008
   Google Scholar
• ClinicalTrials.gov, 7 July 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01156012. http://media.pfizer.com/files/research/pipeline/2008_0228/pipeline_2008_0228.pdf; USAN Web Page, 11 March 2010, http://www.ama-assn.org/ama1/pub/upload/mm/365/taprenepag.pdf; ARVO (Fort Lauderdale), 2010, Abs 175/A398, Page 4 of 13, http://files.abstractsonline.com/Supt/163/2511/SessionPDFNumber/109Gv2.pdf
   Google Scholar
• JP Morgan 27th Ann Healthcare Conf (San Francisco), 2009
   Google Scholar
• ClinicalTrials.gov Web Page, 25 August 2009, NCT00961649
   Google Scholar
• Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007;21(3):167-77
   PubMed Web of Science ®Google Scholar
• Peterson WM, Lampe J, Navratil T. Topical administration of a novel and potent Rho kinase (ROK) inhibitor INS117548 alters the actin cytoskeleton, effectively lowers IOP, and is well tolerated on the ocular surface [poster 3816/A183]. Poster presented at annual meeting of Association for Research in Vision and Ophthalmology; 1st May 2008; Ft. Lauderdale, Florida, USA
   Google Scholar
• Tanihara H, Inatani M, Honjo M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008;126(3):309-15
   PubMed Web of Science ®Google Scholar
• Yingling JD, Arnold JJ, deLong MA, IOP-lowering efficacy and tolerability of AR-12286, a potent kinase inhibitor for the treatment of glaucoma [poster 4063/A225]. Presented in poster session at the annual meeting of the Association for Research in Vision and Ophthalmology; 6 May 2009; Ft. Lauderdale, Florida, USA
   Google Scholar
• Available from: www.clinicaltrials.gov/identifier NCT009002200. [Accessed 2 January 2010]
   Google Scholar
• Zhang M, Rao PV. Blebbistatin a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci 2005;46(11):4130-8
   PubMed Web of Science ®Google Scholar
• Khurana RN, Deng PF, Epstein DL, Rao VP. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp Eye Res 2003;76(1):39-47
   PubMed Web of Science ®Google Scholar
• Mettu PS, Deng PF, Misra UK, Role of lysophosphlipid growth factors in the modulation aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2004;45(7):2263-71
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res 2000;29(3):271-95
   Google Scholar
• Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002;80:629-38
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Hu Y, Vittiow JL, Caldesmon transgene expression disrupts focal adhesion in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. Exp Eye Res 2006;6(82):935-44
   Google Scholar
• Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta 2 for the pathogenesis of the disease. Exp Eye Res 2005;81:1-4
   PubMed Web of Science ®Google Scholar
• Noske W, Hensen J, Wiederholt M. endothelin-like immunoreactivity in aqueous humor of patients with primary open angle glaucoma and cataract. Graefes Arch Clin Exp Ophthalmol 1997;235:551-2
   PubMed Web of Science ®Google Scholar
• Volberg T, Geiger B, Citi S, Bershadky AD. Effect of protein kinase inhibitor H-7 on the contractility, interity and membrane anchorage of the microfilament system. Cell Motil Cytoskel 1994;4(29):321-38
   Google Scholar
• Thieme H, Nuskovski M, Nass JU, Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophtahlmol Vis Sci 2000;(40):1009-11
   Google Scholar
• Tian B, Kaufman PL. Effects of the rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in onkeys. Exp Eye Res 2005;(80):215-25
   PubMedGoogle Scholar
• Khurana RN, Deng PF, Epstein DL, Rao PV. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp Eye Res 2003;76(1):39-47
   PubMed Web of Science ®Google Scholar
• Fuchshofer R, Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res 2009;88(4):683-8
   PubMed Web of Science ®Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53(Suppl 1):107-20
   Google Scholar
• Fuchshofer R, Yu AH, Welge-Lussen U, Tamm ER. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2007;48(2):715-26
   PubMed Web of Science ®Google Scholar
• Brown SS, Spupich JA. Mechanism of action of cytochalasin. Evidence that it binds to actin filament ends. J Cell Biol 1981;88:487-91
   PubMed Web of Science ®Google Scholar
• Svedbergh B, Lutjen-drecoll E, Ober M, Kaufmann PL. Cytochalasin B-induced structural changes in the anterior ocular segment of the cynomolgus monkey. Invest Ophthalmol Vis Sci 1978;17:718-34
   PubMed Web of Science ®Google Scholar
• Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 2009;88:713-17
   PubMed Web of Science ®Google Scholar
• Liu X, Cai S, Glasser A, Effects of H-7 on cultured trabecular meshwork cells. Mol Vis 2001;7:145-3
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Hu Y, vittiow JL, Caldesmon transgene expression disrupts focal adhesion in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. Exp Eye Res 2006;82:935-44
   PubMed Web of Science ®Google Scholar
• Liu X, Hu Y, Filla MS, The effect of C3 transgene expression on actin and cellular adhesion in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Mol Vis 2005;11:1112-21
   PubMed Web of Science ®Google Scholar
• Rao PV, Deng P, Maddala R, Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow. Mol Vis 2005;27(11):288-97
   Google Scholar
• Fuchshofer R, Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res 2009;88(4):683-8
   PubMed Web of Science ®Google Scholar
• Rauhut D, Rohen JW. Electron microscopic study of the trabecular meshwork in alphachymotrypsin glaucoma. Graefes Arch Clin Exp Ophthalmol 1972;184(1):29-41
   Google Scholar
• Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv Ophthalmol 2007;52(Suppl 2):S101-4
   PubMedGoogle Scholar
• Fuchshofer R, Yu AH, Welge-Lussen U, Tamm ER. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2007;48(2):715-26
   PubMed Web of Science ®Google Scholar
• Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007;(4):CD005022
   Google Scholar
• Robin AL, Suan EP, Sjaarda RN, Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol 2009;127(2):173-8
   PubMed Web of Science ®Google Scholar
• Mozaffarieh M, Flammer J. A novel perspective on natural therapeutic approaches in glaucoma therapy. Expert Opin Emerg Drugs 2007;12(2):195-8
   PubMed Web of Science ®Google Scholar